Patent intelligence · EP
EP 3485879
ORALE PHARMAZEUTISCHE FORMULIERUNG ENTHALTEND BAKTERIEN
ORALE PHARMAZEUTISCHE FORMULIERUNG ENTHALTEND BAKTERIEN
Patent details — EP 3485879
- Jurisdiction
- EP
- Status
- granted
- Grant date
- May 22, 2019
- Expiration
- May 17, 2039
- Applicant
- MAAT PHARMA [FR]
- CPC classes
- A61K 9/ 19 A I, A61K 9/ 48 A I, A61K 35/ 745 A I, A61K/3574
Quick answer
EP 3485879 (ORALE PHARMAZEUTISCHE FORMULIERUNG ENTHALTEND BAKTERIEN) is held by MAAT PHARMA [FR]. Status: granted. Granted May 22, 2019. Expires May 17, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- MAAT PHARMA [FR]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 19 A I, A61K 9/ 48 A I, A61K 35/ 745 A I, A61K/3574, A61K/35741, A61K/4714
More from MAAT PHARMA [FR]
Related pharmaceutical patents in our USPTO index.
-
WO 2026013310
COMPOSITION PHARMACEUTIQUE LIQUIDE À BASE DE STIRIPENTOL
granted -
WO 2024194388
PREPARATION DE LEVURE SACCHAROMYCES BOULARDII INACTIVEE
granted -
WO 2023046844
COMPOSITIONS PHARMACEUTIQUES UTILES POUR LA PRÉVENTION OU LE TRAITEMENT D'INFECTIONS VIRALES
granted -
FR 3121841
Traitement des hyperammoniémies
granted -
EP 3964220
PHARMAZEUTISCHE ZUSAMMENSETZUNG ZUR BEHANDLUNG VON OSTEOPOROSE
granted -
CA 3072544
SACCHAROMYCES BOULARDII POUR LE TRAITEMENT DES TROUBLES DE L'HUMEUR
granted -
CA 3065417
TRAITEMENT DE MALADIES ASSOCIEES A UNE DYSREGULATION DE LA VOIE MTOR
granted
Frequently asked questions
What is US patent 3485879?
EP 3485879 (ORALE PHARMAZEUTISCHE FORMULIERUNG ENTHALTEND BAKTERIEN) is held by MAAT PHARMA [FR]. Status: granted. Granted May 22, 2019. Expires May 17, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns EP 3485879?
MAAT PHARMA [FR] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does EP 3485879 expire?
Our index shows an expiration date of May 17, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.